Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cocrystal PharmaCOCP -5.50%23 3-Year EBITDA Growth Rate is 29.40% as of Mar. 2026, which is 263% above its 10-year median of 8.10. GuruFocus rates COCP with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,136 Biotechnology companies, Cocrystal Pharma ranks better than 66.37% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 31.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cocrystal Pharma was 58.80% per year. The lowest was -256.00% per year. And the median was 8.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cocrystal Pharma 3-Year EBITDA Growth Rate Related Terms
COCP vs ANEB, BCDA, PHIO: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Cocrystal Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.40% mean?
Cocrystal Pharma (COCP) has a 3-Year EBITDA Growth Rate of 29.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cocrystal Pharma and its competitors. This is 263% above median its historical median of 8.10. According to the industry distribution chart, Cocrystal Pharma ranks #382 out of 1136 companies in the Biotechnology industry, placing it in the top 33.6%.
Is Cocrystal Pharma's 3-Year EBITDA Growth Rate too high?
Cocrystal Pharma's current 3-Year EBITDA Growth Rate of 29.40% is 263% above median its 10-year median of 8.10. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Cocrystal Pharma's value of 29.40% is 98% above this industry median. Based on the distribution chart, Cocrystal Pharma ranks #382 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cocrystal Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's 3-Year EBITDA Growth Rate compare to ANEB and BCDA?
According to the Biotechnology industry distribution chart, Cocrystal Pharma ranks #382 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Cocrystal Pharma in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Cocrystal Pharma's value of 29.40% is 98% above this benchmark. While the company's 10-year median is 8.10 vs. the industry median of 14.85, Cocrystal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cocrystal Pharma's current 3-Year EBITDA Growth Rate of 29.40% is 98% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cocrystal Pharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cocrystal Pharma's current 3-Year EBITDA Growth Rate is 29.40%, which is 263% above median its own 10-year median of 8.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Cocrystal Pharma (COCP) has a current 3-Year EBITDA Growth Rate of 29.40%. The current 3-Year EBITDA Growth Rate is 29.40%, which is 263% above median its 10-year median of 8.10 and 98% above the Biotechnology industry median of 14.85. Cocrystal Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cocrystal Pharma (COCP), the current 3-Year EBITDA Growth Rate is 29.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
23GF Score
Get the complete analysis for COCP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCP has been successfully added to your 
